• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endocare

Endocare

Endocan Corp ENDO

Last Price$0.01Day Change (%)-6.67%
Open Price$0.01Day Change ($)0.00
Day Range0.01–0.0152-Week Range0.00–0.03

As of Thu 5/5/2016 4:35:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Mylan, Allergan shares fall after Perrigo profit warning

    Mylan, Allergan shares fall after Perrigo profit warning

  2. Endoscopy Devices: Applications and Global Markets to 2020 - Market is expected to grow from $32.5 billion in 2015 to roughly $45.2 billion by 2020 - Research and Markets

    Endoscopy Devices: Applications and Global Markets to 2020 - Market is expected to grow from $32.5 billion in 2015 to roughly $45.2 billion by 2020 - Research and Markets

  3. Global Companion Animals Drug Market Growth of 4.9% CAGR by 2025 - Analysis, Technologies & Forecasts Report 2015-2025 - Key Vendors: Bayer, Boehringer, Elanco - Research and Markets

    Global Companion Animals Drug Market Growth of 4.9% CAGR by 2025 - Analysis, Technologies & Forecasts Report 2015-2025 - Key Vendors: Bayer, Boehringer, Elanco - Research and Markets

  4. Gonorrhea Global Clinical Trials Review, H1, 2016 - Research and Markets

    Gonorrhea Global Clinical Trials Review, H1, 2016 - Research and Markets

  5. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  6. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

    As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

  7. Health Care: 3 Picks in a More Expensive Sector

    Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

  8. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.